SCHEMBL8720711

SCHEMBL8720711

O=C(Nc1ccc2scc(C3=CCN4CCCCC4CC3)c2c1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.44
MAPT P10636 6/20 0.44
TDP1 Q9NUW8 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
RAB9A P51151 3/20 0.38
LMNA P02545 3/20 0.38
HSD11B1 P28845 2/20 0.38
NPC1 O15118 2/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B1 P14061 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
RORC P51449 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8725926 0.92 TDP1 (0.41) TP53MAPTTDP1KMT2AMEN1
SCHEMBL8724021 0.91 HTR1F (0.40) TP53MAPTMAPK1RAB9ANPC1
SCHEMBL8720679 0.90 MAPK14 (0.38) TP53MAPTTDP1KMT2ARAB9A
SCHEMBL8721276 0.89 AVPR1A (0.44) TP53MAPTLMNA
SCHEMBL8723604 0.89 TDP1 (0.39) TP53MAPTTDP1KMT2AMEN1
SCHEMBL8706037 0.88 ALDH1A1 (0.42) TP53MAPTTDP1KMT2AMEN1
SCHEMBL8721285 0.88 KCNQ3 (0.40) TP53MAPTKMT2AMEN1RAB9A
SCHEMBL8720823 0.88 TDP1 (0.39) TP53MAPTTDP1KMT2AMEN1
SCHEMBL8721911 0.88 KMT2A (0.43) TP53MAPTTDP1KMT2AMEN1
SCHEMBL8725934 0.87 OPRM1 (0.36) TP53MAPTTDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D TP53 676/4885MAPT 3544/4885TDP1 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.